Bluejay diagnostics, inc. announces its pre-submission filing package for the symphony il-6 test is with the fda

Acton, mass., jan. 31, 2022 (globe newswire) -- bluejay diagnostics, inc. (nasdaq: bjdx) (“bluejay”, “the company”) a late-stage, pre-revenue diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced that it has filed a pre-submission package for the symphony il-6 test with the u.s. food and drug administration (“fda” or “the agency”). the purpose of this filing is to request feedback from the agency prior to submitting a medical device marketing application. the pre-submission package will allow the fda to review and comment on the company's plans for clinical trials and analytical testing.
BJDX Ratings Summary
BJDX Quant Ranking